WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407126
Description: GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X displayed activity in vivo against NUT-midline carcinoma, multiple myeloma, mixed-lineage leukemia, and acute myeloid leukemia. Bromodomain and extra-terminal (BET) proteins belong to a class of proteins collectively called epigenetic "readers". BET bromodomains have emerged as promising drug targets for treatment of cancers, inflammatory diseases, and other medical conditions.
MedKoo Cat#: 407126
Chemical Formula: C26H22ClN5O3
Exact Mass: 487.14112
Molecular Weight: 487.94
Elemental Analysis: C, 64.00; H, 4.54; Cl, 7.27; N, 14.35; O, 9.84
GW-841819X is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: GW-841819X; GW841819X; GW 841819X; GW 841819; GW841819; GW-841819.
IUPAC/Chemical Name: benzyl (R)-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)carbamate
InChi Key: GWCVVMLABUZZCV-DEOSSOPVSA-N
InChi Code: InChI=1S/C26H22ClN5O3/c1-16-30-31-25-24(29-26(33)35-15-17-6-4-3-5-7-17)28-23(18-8-10-19(27)11-9-18)21-14-20(34-2)12-13-22(21)32(16)25/h3-14,24H,15H2,1-2H3,(H,29,33)/t24-/m0/s1
SMILES Code: O=C(OCC1=CC=CC=C1)N[C@H]2C3=NN=C(C)N3C4=CC=C(OC)C=C4C(C5=CC=C(Cl)C=C5)=N2
The following data is based on the product molecular weight 487.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Bamborough, P. and C.-W. Chung Screening inhibitors of human BRD-2 to 4 bromodomains binding to acetylated lysine residues of their physiol. partner proteins: 66pp.
Baud, M. G. J., E. Lin-Shiao, et al. "A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes." Science (Washington, DC, U. S.) 346(6209): 638-641.
Chung, C.-w., H. Coste, et al. "Discovery and characterization of small molecule inhibitors of the BET family bromodomains." J. Med. Chem. 54(11): 3827-3838.
Crowe, M., A. C.-M. Daugan, et al. Condensed azepine derivatives as bromodomain inhibitors and their preparation and use in the treatment of cancer, chronic autoimmune and inflammatory diseases: 109pp.
Finkel, T. H., J. Wang, et al. Compositions and methods comprising bromodomain (BET) antagonists for the treatment of HIV infection: 37pp.
Finkel, T. H., J. Wang, et al. Compositions and methods for the treatment of HIV infection using a bromodomain and extra-terminal (BET) protein antagonist: 27 pp., Cont.-in-part of Appl. No. PCT/US2012/048809.
Freidinger, R. M., B. E. Evans, et al. (1992). Preparation of triazolobenzodiazepines as CCK and gastrin antagonists: 93 pp.
Mirguet, O., R. Gosmini, et al. "Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains." J. Med. Chem. 56(19): 7501-7515.
Ursu, A. and H. Waldmann "Hide and seek: Identification and confirmation of small molecule protein targets." Bioorg. Med. Chem. Lett. 25(16): 3079-3086.
Zhao, Y., C.-Y. Yang, et al. "The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development." J. Med. Chem. 56(19): 7498-7500.